research
Chemotherapy Summons the Cells That Shield the Tumor
An IL-1? inflammatory cascade recruited neutrophils whose extracellular traps weakened later treatment in ovarian-cancer models.
Summary
An IL-1? inflammatory cascade recruited neutrophils whose extracellular traps weakened later treatment in ovarian-cancer models.
Wistar researchers compared tumors before and after chemotherapy and found higher interleukin-1 beta, especially in poor responders. In engineered mouse models, disrupting IL-1? signaling improved tumor shrinkage; laboratory work traced a path through neutrophil recruitment, T-cell exhaustion, and web-like extracellular traps that reduced drug effectiveness. Patient samples echoed parts of that pattern, but blocking the pathway remains a therapeutic hypothesis, not an established treatment.
Why it matters
An IL-1? inflammatory cascade recruited neutrophils whose extracellular traps weakened later treatment in ovarian-cancer models.
Limits and context
- signaling improved tumor shrinkage; laboratory work traced a path through neutrophil recruitment, T-cell exhaustion, and web-like extracellular traps that reduced drug effectiveness.
- Patient samples echoed parts of that pattern, but blocking the pathway remains a therapeutic hypothesis, not an established treatment.
Key claims
An IL-1? inflammatory cascade recruited neutrophils whose extracellular traps weakened later treatment in ovarian-cancer models.
Qualification: signaling improved tumor shrinkage; laboratory work traced a path through neutrophil recruitment, T-cell exhaustion, and web-like extracellular traps that reduced drug effectiveness.
Evidence: source-2026-07-24-013
Sources
- Wistar Institute via Newswise: Ovarian chemotherapy resistance mechanismWistar Institute via Newswise · official announcement
Corrections
No corrections have been recorded for this story.